On October 13, 2017, pursuant to the terms of the Merger Agreement, Holdco completed its acquisition of the SciClone Pharmaceuticals, Inc. (Company) through the merger of Holdco (Merger Sub) with and into the Company, with the Company continuing after the Merger as the surviving corporation and subsidiary of Holdco. Upon completion of the Merger, Ting Ping Ping, who constituted the Board of Directors of Merger Sub, became the director of the Company, and each of the six directors of the Company immediately prior to the Effective Time (Jon S. Saxe, Friedhelm Blobel, Ph.D., Nancy T. Chang, Ph.D., Richard J. Hawkins, Gregg A. Lapointe and Simon Li) are no longer directors of the Company.